MIR191 (MicroRNA 191)

The overexpression of miR-139-3p in BC cells enhanced cisplatin, olaparib, and irradiation (IR) sensitivity. The diagnostic model based on the four circulating miRNAs could serve as a tool for the liquid biopsy of BC. Targeting the miR-139-3p/RPA2 axis may have potential in modulating the DNA damage pathway in BC.

The approach combines high sensitivity, wide dynamic range, quantitative precision, and spatial resolution, allowing amplification-free monitoring of miRNA expression in live cells. This versatile platform provides a powerful tool for intracellular biosensing, with potential applications in live-cell diagnostics, therapeutic response profiling, and studies of single-cell gene regulation.

The gradual increase in specific miRNAs with lesion severity and HPV infection suggests their role in cervical carcinogenesis. The identified miRNAs may serve as promising non-invasive biomarkers for early detection and monitoring of HPV-associated cervical lesions.

Inhibition of exosomal miR-191 attenuated CRC progression by inducing ferroptosis in macrophages. This study revealed a novel mechanism by which exosomal miR-191 modulates the tumor microenvironment.

Pathway enrichment linked these deregulated miRNAs to key oncogenic networks, particularly PI3K/AKT/mTOR, Wnt/β-catenin, and EMT regulation, demonstrating conserved molecular mechanisms shared with human BC and highlighting their potential as biomarkers in CMTs. These findings provide insights into the molecular mechanisms of CMT adenocarcinoma and suggest the potential of miRNA-based biomarkers for the diagnosis and treatment of CMTs.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.

These findings highlight the therapeutic potential of MFB-ICSS as a non-pharmacological intervention in AD. Furthermore, this study confirms NRF2 as a target of miR-495 in the context of AD.

Here, we observed an interaction between lncRNA ADIRF-AS1and hsa-miR-191-5p, and also, ADIRFAS1 downstream effects on EGR1 in EC, that seems may be a suggesting therapeutic and diagnostic targets. Further research could explore its clinical relevance in endometrial carcinoma.

However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.

Our findings highlight the role of GaMSC-Exos in mediating the intercellular transfer of miRNA-191-5p, which facilitates the PMT of glioma. The process underlying the enhanced aggressiveness and PMT is driven by miR-191-5p, promoting glioma progression by targeting PTEN and activating the PI3K/AKT signaling pathway.